Structural topology defines protective CD8 + T cell epitopes in the HIV proteome | Zendy

Gaurav D. Gaiha | Zendy; Elizabeth J. Rossin | Zendy; Jonathan M. Urbach | Zendy; Christian Landeros | Zendy; David R. Collins | Zendy; Chioma Nwonu | Zendy; Itai Muzhingi | Zendy; Melis N. Anahtar | Zendy; Olivia Mae Waring | Zendy; Alicja PiechockaTrocha | Zendy; Michael T. Waring | Zendy; Daniel Worrall | Zendy; Musie Ghebremichael | Zendy; Ruchi M. Newman | Zendy; Karen A. Power | Zendy; Todd M. Allen | Zendy; James Chodosh | Zendy; Bruce D. Walker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Structural topology defines protective CD8 ⁺ T cell epitopes in the HIV proteome

Author(s) -

Gaurav D. Gaiha,

Elizabeth J. Rossin,

Jonathan M. Urbach,

Christian Landeros,

David R. Collins,

Chioma Nwonu,

Itai Muzhingi,

Melis N. Anahtar,

Olivia Mae Waring,

Alicja PiechockaTrocha,

Michael T. Waring,

Daniel Worrall,

Musie Ghebremichael,

Ruchi M. Newman,

Karen A. Power,

Todd M. Allen,

James Chodosh,

Bruce D. Walker

Publication year - 2019

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.aav5095

Subject(s) - epitope , computational biology , biology , proteome , cd8 , virology , peptide sequence , antigen , topology (electrical circuits) , genetics , gene , mathematics , combinatorics

Structure-based immunogen design Vaccine design for highly mutable pathogens is hindered by a paucity of conserved immunogenic epitopes. Gaihaet al. employed a structure-based technique using network theory to assign scores to protein structure in order to infer mutational constraints (see the Perspective by McMichael and Carrington). The authors validated the method on proteins with published functional outcomes and then assessed mutational constraints within the HIV proteome. Highly networked residues strongly associated with immune control of HIV infection and may lead to protective immunogens for pathogens for which there is currently no efficient vaccine.Science , this issue p.480 ; see also p.438

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research